These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
132 related articles for article (PubMed ID: 11702302)
1. Risk-benefit assessment of methotrexate in the treatment of severe psoriasis. Kuijpers AL; van de Kerkhof PC Am J Clin Dermatol; 2000; 1(1):27-39. PubMed ID: 11702302 [TBL] [Abstract][Full Text] [Related]
2. The value of dynamic hepatic scintigraphy and serum aminoterminal propeptide of type III procollagen for early detection of methotrexate-induced hepatic damage in psoriasis patients. vanDooren-Greebe RJ; Kuijpers AL; Buijs WC; Kniest PH; Corstens FH; Nagengast FM; de Boo T; Willems JL; Duller P; van de Kerkhof PC Br J Dermatol; 1996 Mar; 134(3):481-7. PubMed ID: 8731673 [TBL] [Abstract][Full Text] [Related]
3. The use of transient elastography and FibroTest for monitoring hepatotoxicity in patients receiving methotrexate for psoriasis. Lynch M; Higgins E; McCormick PA; Kirby B; Nolan N; Rogers S; Lally A; Vellinga A; Omar H; Collins P JAMA Dermatol; 2014 Aug; 150(8):856-62. PubMed ID: 24964792 [TBL] [Abstract][Full Text] [Related]
4. Methotrexate in psoriasis: 26 years' experience with low-dose long-term treatment. Haustein UF; Rytter M J Eur Acad Dermatol Venereol; 2000 Sep; 14(5):382-8. PubMed ID: 11305380 [TBL] [Abstract][Full Text] [Related]
5. Serum aminoterminal propeptide of type III procollagen in psoriasis and psoriatic arthritis: relation to liver fibrosis and arthritis. Zachariae H; Aslam HM; Bjerring P; Søgaard H; Zachariae E; Heickendorff L J Am Acad Dermatol; 1991 Jul; 25(1 Pt 1):50-3. PubMed ID: 1880254 [TBL] [Abstract][Full Text] [Related]
6. Monitoring patients on methotrexate: hepatic fibrosis not seen in patients with normal serum assays of aminoterminal peptide of type III procollagen. Maurice PD; Maddox AJ; Green CA; Tatnall F; Schofield JK; Stott DJ Br J Dermatol; 2005 Mar; 152(3):451-8. PubMed ID: 15787813 [TBL] [Abstract][Full Text] [Related]
7. Comparative tolerability of systemic treatments for plaque-type psoriasis. McClure SL; Valentine J; Gordon KB Drug Saf; 2002; 25(13):913-27. PubMed ID: 12381213 [TBL] [Abstract][Full Text] [Related]
9. Liver fibrosis in patients with psoriasis and psoriatic arthritis on long-term, high cumulative dose methotrexate therapy. Lindsay K; Fraser AD; Layton A; Goodfield M; Gruss H; Gough A Rheumatology (Oxford); 2009 May; 48(5):569-72. PubMed ID: 19273538 [TBL] [Abstract][Full Text] [Related]
10. Replacement of routine liver biopsy by procollagen III aminopeptide for monitoring patients with psoriasis receiving long-term methotrexate: a multicentre audit and health economic analysis. Chalmers RJ; Kirby B; Smith A; Burrows P; Little R; Horan M; Hextall JM; Smith CH; Klaber M; Rogers S Br J Dermatol; 2005 Mar; 152(3):444-50. PubMed ID: 15787812 [TBL] [Abstract][Full Text] [Related]
11. Assessment and management of methotrexate hepatotoxicity in psoriasis patients: report from a consensus conference to evaluate current practice and identify key questions toward optimizing methotrexate use in the clinic. Barker J; Horn EJ; Lebwohl M; Warren RB; Nast A; Rosenberg W; Smith C; J Eur Acad Dermatol Venereol; 2011 Jul; 25(7):758-64. PubMed ID: 21198946 [TBL] [Abstract][Full Text] [Related]
12. Comment on: Liver fibrosis in patients with psoriasis and psoriatic arthritis on long-term, high cumulative dose methotrexate therapy. Boffa MJ; Smith A; Chalmers RJ Rheumatology (Oxford); 2009 Nov; 48(11):1464; author reply 1465. PubMed ID: 19671697 [No Abstract] [Full Text] [Related]
13. Methotrexate revisited: effects of long-term treatment in psoriasis. Van Dooren-Greebe RJ; Kuijpers AL; Mulder J; De Boo T; Van de Kerkhof PC Br J Dermatol; 1994 Feb; 130(2):204-10. PubMed ID: 8123573 [TBL] [Abstract][Full Text] [Related]
14. Monitoring liver function during methotrexate therapy for psoriasis: are routine biopsies really necessary? Thomas JA; Aithal GP Am J Clin Dermatol; 2005; 6(6):357-63. PubMed ID: 16343024 [TBL] [Abstract][Full Text] [Related]
15. [Methotrexate therapy in psoriasis]. Bournerias I Rev Prat; 2004 Jan; 54(1):52-5. PubMed ID: 15049601 [TBL] [Abstract][Full Text] [Related]
16. Etanercept therapy allows the tapering of methotrexate and sustained clinical responses in patients with moderate to severe psoriasis. Yamauchi PS; Lowe NJ Int J Dermatol; 2008 Feb; 47(2):202-4. PubMed ID: 18211500 [TBL] [Abstract][Full Text] [Related]
17. Benefit-risk analysis of adalimumab versus methotrexate and placebo in the treatment of moderate to severe psoriasis: comparison of adverse event-free response days in the CHAMPION trial. Reich K; Signorovitch J; Ramakrishnan K; Yu AP; Wu EQ; Gupta SR; Bao Y; Mulani PM J Am Acad Dermatol; 2010 Dec; 63(6):1011-8. PubMed ID: 20933301 [TBL] [Abstract][Full Text] [Related]
18. Validity of noninvasive markers of methotrexate-induced hepatotoxicity: a retrospective cohort study. Martyn-Simmons CL; Rosenberg WM; Cross R; Wong T; Smith CH; Barker JN Br J Dermatol; 2014 Aug; 171(2):267-73. PubMed ID: 24942271 [TBL] [Abstract][Full Text] [Related]
19. Systemic methotrexate treatment in childhood psoriasis: further experience in 24 children from India. Kaur I; Dogra S; De D; Kanwar AJ Pediatr Dermatol; 2008; 25(2):184-8. PubMed ID: 18429775 [TBL] [Abstract][Full Text] [Related]
20. Methotrexate and other chemotherapeutic agents used to treat psoriasis. Jeffes EW; Weinstein GD Dermatol Clin; 1995 Oct; 13(4):875-90. PubMed ID: 8785891 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]